European Pharmacopoeia -ph. Eur.- Monograph Tablets -0478- Instant

Monograph 0478 states that impurities come from two sources:

Perhaps the most intriguing part of Monograph 0478 is its flexibility regarding form. It legally defines various tablet types that modern patients take for granted:

When a tablet features a break-mark (score line) meant for dose subdivision, the manufacturer must validate that the split parts remain uniform. According to the standard test protocol: The Ph.Eur. approach to tablet splitting European Pharmacopoeia -ph. Eur.- Monograph Tablets -0478-

Ph. Eur. 2.9.6 (or 2.9.40) If a tablet contains less than 2 mg or less than 2% (w/w) of an active substance, Uniformity of Mass is not sufficient . You must perform Uniformity of Content via an assay (usually HPLC) on 10 individual tablets.

The label must clearly state:

If a tablet fails dissolution Stage 1 (e.g., 4 tablets pass, 2 tablets release 70% vs Q=75%), you may proceed to Stage 2 (12 more tablets) or Stage 3 (total 24 tablets). But failure of Stage 3 = batch destruction.

Ph. Eur. 2.9.1 Apparatus: Basket-rack assembly (6 glass tubes, 10 mesh screens) oscillating 29-32 cycles/min in water at 37°C ± 2°C. Monograph 0478 states that impurities come from two

The European Pharmacopoeia (Ph. Eur.) monograph for tablets (0478) provides a comprehensive description of the requirements for tablets, including their quality, purity, and strength. Manufacturers must meet these requirements to ensure the quality of their tablet products and to comply with regulatory requirements in Europe. The monograph plays a critical role in ensuring the quality of tablet products and provides a common language and set of standards for regulatory authorities, manufacturers, and control laboratories. By following this monograph, manufacturers can ensure that their products are of equivalent quality and meet the required standards for the European market.

Monograph defines tablets as solid pharmaceutical dosage forms containing a single dose of one or more active substances. They are typically obtained by compressing uniform volumes of particles and are intended for oral administration, though some sub-types may be intended for other routes. Core Quality Requirements approach to tablet splitting Ph

The active substance(s) must be identified using the tests prescribed in the specific monograph for that substance (e.g., spectroscopy, chromatography).

Monograph 0478 applies universally to solid preparations containing a single dose of one or more active substances. These are obtained by compressing uniform volumes of particles or by other specialized manufacturing techniques like freeze-drying (lyophilisation) or molding.